| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536996 | Vaccine | 2017 | 7 Pages |
Abstract
PCV13 implementation has had a strong impact on number of CAP cases with high levels of CRP and/or PCT in children but no impact on that with low levels of these two biomarkers. Five years after PCV13 implementation, a sustained reduction in CAP cases is observed.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Corinne Levy, Sandra Biscardi, Marie Aliette Dommergues, François Dubos, Laure Hees, Karine Levieux, Marie Aurel, Philippe Minodier, Ferielle Zenkhri, Robert Cohen,